Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses recognition and treatment of CAR T-cell therapy-related side effects, including novel insights into the pathophysiology of long-term cytopenias. Close monitoring and timely intervention with tocilizumab with or without corticosteroids remain the best management strategies for cytokine release syndrome (CRS). The pathogenesis of neurotoxicity is not fully understood and it remains very challenging to manage. Similar to CRS management, neurotoxicity needs to be promptly recognized. Additionally, Prof. Subklewe shares the latest updates regarding prolonged cytopenias. This interview took place during the 3rd European CAR T-cell Meeting.
